Newsroom | 30703 results

LYON, Frankrijk--(BUSINESS WIRE)--Brenus Pharma heeft vandaag een uitbreiding van zijn Serie A-financieringsronde met € 11 miljoen ($ 12,6 miljoen) aangekondigd, waarmee het totale opgehaalde kapitaal sinds de oprichting op € 38 miljoen ($ 43,5 miljoen) komt. Deze financiering weerspiegelt de succesvolle realisatie van mijlpalen op het gebied van klinische ontwikkeling, regelgeving en bedrijfsontwikkeling. Hiermee wordt het risicoprofiel van STC-1010 (NCT06934538): de belangrijkste in-vivo-immu...

LYON, France--(BUSINESS WIRE)--Brenus Pharma a annoncé aujourd'hui une extension de 11 millions d'euros (12,6 millions de dollars) à son tour de table de série A, portant le capital total levé depuis sa création à 38 millions d'euros (43,5 millions de dollars). Ce financement témoigne d'une exécution impeccable des étapes clés en matière de développement clinique, réglementaire et commercial, et contribue à réduire les risques liés au STC-1010 (NCT06934538), son principal candidat en phase clin...

LYON, Frankreich--(BUSINESS WIRE)--Brenus Pharma gab heute eine Aufstockung seiner Serie-A-Finanzierungsrunde um 11 Millionen Euro (12,6 Mio. US-Dollar) bekannt, womit sich das seit der Gründung eingeworbene Gesamtkapital auf 38 Millionen Euro (43,5 Mio. US-Dollar) beläuft. Diese Finanzierung spiegelt die erfolgreiche Umsetzung zahlreicher Meilensteine in den Bereichen klinische Entwicklung, Zulassungsverfahren und Geschäftsentwicklung wider und trägt dazu bei, die Risiken im Zusammenhang mit S...

LIONE, Francia--(BUSINESS WIRE)--Brenus Pharma oggi ha annunciato un'estensione di 11 milioni di euro (12,6 milioni di dollari) del suo round di finanziamento di Serie A, portando a 38 milioni di euro (43,5 milioni di dollari) il capitale totale raccolto fin dall'inizio. Questo finanziamento riflette la forte esecuzione attraverso tappe fondamentali in ambito clinico, normativo e di sviluppo commerciale, riducendo i rischi legati al STC-1010 (NCT06934538): la principale immunoterapia in vivo in...

LYON, Francia--(BUSINESS WIRE)--Brenus Pharma ha anunciado hoy una ampliación de 11 millones de euros (12,6 millones de dólares) de su ronda de financiación Serie A, con la que eleva a 38 millones de euros (43,5 millones de dólares) el capital captado desde su fundación. Esta inversión respalda los avances logrados por la empresa en los ámbitos clínico, regulatorio y de desarrollo de negocio, refuerza el desarrollo de STC-1010 (NCT06934538), su principal inmunoterapia in vivo en fase clínica pa...

LYON, France--(BUSINESS WIRE)--Brenus Pharma today announced an €11 million ($12.6M) extension to its Series A round, bringing total capital raised since inception to €38 million ($43.5M). This funding reflects strong execution across clinical, regulatory, and business development milestones, de-risking STC-1010 (NCT06934538): lead clinical-stage in-vivo immunotherapy for MSS mCRC, while positioning the company’s proprietary platform for multi-asset expansion. The round was supported by strong...

WASHINGTON--(BUSINESS WIRE)--Infleqtion (NYSE: INFQ), a global leader in quantum computing and quantum sensing powered by neutral-atom technology, today announced that its CEO, Matthew Kinsella, will testify before the U.S. House of Representatives Committee on Natural Resources to discuss the Quantum-Enhanced Critical Minerals Mapping Act of 2026. The committee will hold a legislative hearing Tuesday, July 21, at 10:15 a.m. EDT. Viewers can stream live on the YouTube feed, and additional infor...

AUSTIN, Texas--(BUSINESS WIRE)--The last paragraph in the release after the boilerplate has been removed.The updated release reads:INTRABIO ANNOUNCES PUBLICATION OF NEW RESEARCH SHOWING A DIRECT, BIDIRECTIONAL EFFECT ON LYSOSOMAL FUNCTION WITH LEVACETYLLEUCINEIntraBio today announced the publication of new research in PLOS ONE describing a newly identified way that levacetylleucine, the active ingredient in AQNEURSA®, acts directly on cellular lysosomal function.The study, conducted by researche...

EVANSTON, Ill.--(BUSINESS WIRE)--Flashpoint Therapeutics, a biotechnology company pioneering the development of transformative nanomedicines, proudly congratulates its founder, Professor Chad A. Mirkin, on being named the recipient of the 2027 Priestley Medal by the American Chemical Society (ACS). This accolade stands as the premier distinction in the field of chemistry, celebrating Prof. Mirkin’s sweeping innovations in nanotechnology and his distinguished service to the global scientific com...

LONDON--(BUSINESS WIRE)--Planet Labs UK, a leading provider of daily data and insights about change on Earth, today announced the opening of its new office in central London. It marks a significant milestone in Planet's commitment to the United Kingdom as a critical partner within the high-growth space economy. The office will serve as a national hub for AI and analytics partnerships, placing Planet at the epicentre of Britain's leading commercial technology sector. This strategic location, ste...